Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis
Steven E. Van der Plas, Hans Kelgtermans, Oscar Mammoliti, Christel Menet, Giovanni Tricarico, Ann De Blieck, Caroline Joannesse, Tom De Munck, Dominique Lambin, Marlon Cowart, Sébastien Dropsit, Sébastien L. X. Martina, Maarten Gees, Anne-Sophie Wesse, Katja Conrath, Martin Andrews
Abstract
Cystic fibrosis (CF) is a life-threatening recessive genetic disease caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR). With the discovery of Ivacaftor and Lumacaftor, it has been shown that administration of one or more small molecules can partially restore the CFTR function. Correctors are small molecules that enhance the amount of CFTR on the cell surface, while potentiators improve the gating function of the CFTR channel. Herein, we describe the discovery and optimization of a novel potentiator series. Scaffold hopping, focusing on retaining the different intramolecular contacts, was crucial in the whole discovery process to identify a novel series devoid of genotoxic liabilities. From this series, the clinical candidate GLPG2451 was selected based on its pharmacokinetic properties, allowing QD dosing and based on its low CYP induction potential.